| Trial ID: | L5135 |
| Source ID: | NCT03985384
|
| Associated Drug: |
Semaglutide 2 Mg/1.5 Ml Subcutaneous Solution
|
| Title: |
Semaglutide Treatment On Coronary Progression
|
| Acronym: |
STOP
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Coronary Artery Disease
|
| Interventions: |
DRUG: Semaglutide 2 MG/1.5 ML Subcutaneous Solution|DRUG: Placebo
|
| Outcome Measures: |
Primary: Rate of change in non-calcified plaque volume, Rate of change in non-calcified plaque volume, 12 months | Secondary: Rate of change in total plaque volume, Rate of change in total plaque volume, 12 months
|
| Sponsor/Collaborators: |
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
140
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-04-30
|
| Completion Date: |
2022-12-27
|
| Results First Posted: |
|
| Last Update Posted: |
2023-10-05
|
| Locations: |
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, 90502, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03985384
|
